- Home
- NRIX vs QURE Comparison
NRIX vs QURE Comparison
Compare NRIX & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- QURE
- Stock Information
- Founded
- NRIX 2009
- QURE 1998
- Country
- NRIX United States
- QURE Netherlands
- Employees
- NRIX N/A
- QURE N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- NRIX Health Care
- QURE Health Care
- Exchange
- NRIX Nasdaq
- QURE Nasdaq
- Market Cap
- NRIX 728.6M
- QURE 866.3M
- IPO Year
- NRIX 2020
- QURE 2007
- Fundamental
- Price
- NRIX $9.91
- QURE $17.95
- Analyst Decision
- NRIX Strong Buy
- QURE Strong Buy
- Analyst Count
- NRIX 15
- QURE 11
- Target Price
- NRIX $29.13
- QURE $39.91
- AVG Volume (30 Days)
- NRIX 733.8K
- QURE 938.5K
- Earning Date
- NRIX 10-10-2025
- QURE 11-04-2025
- Dividend Yield
- NRIX N/A
- QURE N/A
- EPS Growth
- NRIX N/A
- QURE N/A
- EPS
- NRIX N/A
- QURE N/A
- Revenue
- NRIX $88,381,000.00
- QURE $14,337,000.00
- Revenue This Year
- NRIX $74.59
- QURE N/A
- Revenue Next Year
- NRIX N/A
- QURE $301.10
- P/E Ratio
- NRIX N/A
- QURE N/A
- Revenue Growth
- NRIX 41.86
- QURE N/A
- 52 Week Low
- NRIX $8.18
- QURE $4.45
- 52 Week High
- NRIX $29.56
- QURE $19.18
- Technical
- Relative Strength Index (RSI)
- NRIX 47.82
- QURE 74.71
- Support Level
- NRIX $8.97
- QURE $16.56
- Resistance Level
- NRIX $9.68
- QURE $16.68
- Average True Range (ATR)
- NRIX 0.55
- QURE 0.81
- MACD
- NRIX 0.04
- QURE 0.24
- Stochastic Oscillator
- NRIX 55.13
- QURE 93.93
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.